Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.
Usona Institute Beginning Phase 2 Clinical Trials Using Psilocybin to Treat Major Depressive Disorder
Enrollment of study volunteers is expected to start within the next two months.
Increased mindfulness and decreased anxiety, depression, and stress were seen right away, becoming more significant four weeks after dosing.
The answer is yes and no. It's a matter of perspective.
Improvements in depression and anxiety are associated with greater intensity of mystical experiences and higher ratings of the spiritual significance and personal meaning.
Bruce Tobin is asking Health Canada to approve psilocybin to treat anxiety and depression in end-of-life patients.
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Researchers push to move psilocybin from Schedule I to Schedule IV if Phase III clinical trials are successful.
The FDA will work to expedite the development and review of the drug so it can get to patients as soon as possible.